Abstract
Orthoclone OKT3 (muromonab-CD3), a murine monoclonal antibody that virtually eliminates circulating T cells and inhibits medullary lymphocyte function, has recently been found effective in reversing stubborn severe allograft rejection after heart transplantation. To determine the influence of OKT3 therapy on the development of infections in cardiac allograft recipients, we compared the frequency and severity of infection in 16 patients who underwent treatment for cardiac allograft rejection at our institution from July 1985 through November 1986. these included 11 patients on OKT3 therapy and 5 patients on a conventional immuno-suppressive regimen. With 2 exceptions late in the trial, OKT3 was used only as a rescue therapy, for patients who did not respond to standard adjunctive therapy consisting of high doses of corticosteroids or antithymocyte globulin, or both. The 5 patients who did not receive OKT3 responded to adjunctive therapy and were in general not as ill as the OKT3 recipients. Our protocol specified that patients in both groups be studied during the 6 weeks (42 days) immediately following transplantation. During this period of study, 6 patients in our 11 member OKT3 group experienced 25 infectious processes, 22 of which occurred in only 3 patients and 14 of which were considered life-threatening (2 of the 3 very ill patients died during the study period). These infections were found most often in the gastrointestinal and genitourinary tracts, involved both bacterial and nonbacterial pathogens, and developed about 2 weeks after the initiation of therapy. By comparison, 2 patients in our 5-member non-OKT3 group experienced 3 infectious processes during the study period, and these were not life-threatening. Because of the occurrence in the OKT3 group of 22 of the 25 infections in only 3 patients, these early results were skewed, but a trend was noted towards a higher incidence of bacterial infection in the OKT3 group. A larger and longer-term trial is under way to evaluate the trend. (Texas Heart Institute Journal 1988;15:102-106)
Keywords: Cardiac transplantation
Keywords: Immunosuppression
Keywords: Immunosuppressive agents
Keywords: Orthoclone OKT3
Keywords: antibodies, monoclonal
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med. 1985 Aug 8;313(6):337–342. doi: 10.1056/NEJM198508083130601. [DOI] [PubMed] [Google Scholar]
- Gilbert E. M., Dewitt C. W., Eiswirth C. C., Renlund D. G., Menlove R. L., Freedman L. A., Herrick C. M., Gay W. A., Bristow M. R. Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. Am J Med. 1987 Feb;82(2):202–206. doi: 10.1016/0002-9343(87)90056-8. [DOI] [PubMed] [Google Scholar]
- Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
- Prentice H. G., Blacklock H. A., Janossy G., Bradstock K. F., Skeggs D., Goldstein G., Hoffbrand A. V. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet. 1982 Mar 27;1(8274):700–703. doi: 10.1016/s0140-6736(82)92619-8. [DOI] [PubMed] [Google Scholar]
- Sweeney M. S., Sinnott J. T., 4th, Cullison J. P., Weinstein S. S. The use of OKT3 for stubborn heart allograft rejection: an advance in clinical immunotherapy? J Heart Transplant. 1987 Nov-Dec;6(6):324–328. [PubMed] [Google Scholar]